Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fusion Pharmaceuticals (FUSN)
NASDAQ:FUSN
RESEARCH TOOLSreports
Holding FUSN?
Track your performance easily
FUSN Stock Chart & Stats
Day’s Range$21.45 - $21.59
52-Week Range― - ―
Previous Close$21.52
Volume6.09M
Average Volume (3M)N/A
Market Cap
$1.83B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$21.69Price Target Upside0.65% Upside
Rating ConsensusHold
Number of Analyst Covering13
Fusion Pharmaceuticals News
PremiumCompany Announcements
Fusion Pharmaceuticals’ Acquisition and Governance Overhaul
PremiumPress Releases
Acquisition of Fusion Pharmaceuticals Completed
PremiumCompany Announcements
Fusion Pharmaceuticals Shareholders Back Major AstraZenica Deal
Bulls Say, Bears Say
Bulls Say
Acquisition PremiumAstraZeneca's offer to acquire Fusion Pharmaceuticals at a premium demonstrates strong confidence in Fusion's value and future potential.
Clinical DevelopmentEncouraging Phase II TATCIST data for Fusion's FPI-2265 suggests significant treatment effectiveness, with potential for widespread use in prostate cancer treatment.
Strategic AcquisitionAstraZeneca's strategic move to acquire Fusion aligns with its existing prostate cancer franchise, potentially enhancing its market position with Fusion's radiopharmaceuticals.
Bears Say
Analyst RecommendationDowngrading to Hold from Buy given announced acquisition.
Clinical Trial OutcomesPotential for significant negative pressure on the stock if the readout is less favorable than hoped.
Market CompetitionNo potential seen for a higher competitive bid.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FUSN FAQ
What was Fusion Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Fusion Pharmaceuticals’s market cap?
Currently, no data Available
When is Fusion Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Fusion Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Fusion Pharmaceuticals overvalued?
According to Wall Street analysts Fusion Pharmaceuticals’s price is currently Undervalued.
Does Fusion Pharmaceuticals pay dividends?
Fusion Pharmaceuticals does not currently pay dividends.
What is Fusion Pharmaceuticals’s EPS estimate?
Fusion Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Pharmaceuticals have?
Currently, no data Available
What happened to Fusion Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fusion Pharmaceuticals?
Among the largest hedge funds holding Fusion Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Fusion Pharmaceuticals’s shares valued at 146M.
---
Fusion Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc is a clinical stage bio-pharmaceutical company focused on developing alpha therapeutics for curing cancer.
---
FUSN Stock 12 Month Forecast
Average Price Target
$21.69
▲(0.65% Upside)
Technical Analysis
MacroGenics
―
Crispr Therapeutics AG
―
Arrowhead Pharmaceuticals
―
Bio-Path Holdings
―
Best Analysts Covering FUSN
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+282.32%
reiterated a buy rating 10 months ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +282.32% per trade.
---